Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.

Related Keywords

Germany , United States , North Carolina , Massachusetts , Washington , Boston , Duke University , Berlin , America , American , German , Windtree Therapuetics , Jamesl Januzzi , Bristol Myers Squibb , Bristol Myers , G Michael Felker , Amgen , American Heart Association , Boehringer Ingelheim , Novartis , Pfizer , Astrazeneca , Novartis Pharmaceuticals , Cardiovascular Research , Blood Institute , National Heart , Harvard Medical School , German Center , Imbria Pharmaceuticals , Siemens , Medtronic , Trustee Of The American College Cardiology , Massachusetts General Hospital , Medscape Cardiology , Kansas City Cardiomyopathy Questionnaire , Heart Failure Society , America Annual Scientific Meeting , American College , Applied Therapeutics , Roche Diagnostics , American Regent , Cardiac Dimension , Failure Society , Breaking Clinical Trials Session , Mitral Regurgitation , Heart Failure , Reduced Ejection , Presented October , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Echocardiography , Echocardiogram , Echo , Valve Repair , Renin Angiotensin System , Renin Angiotensin Aldosterone System , As Renin Angiotensin System , Aas Renin Angiotensin Aldosterone System , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Health A ,